Keeping Track: Gilead Aims To Expand TAF To HBV; BioMarin's Kyndrisa Get Complete Reponse

 
• By Bridget Silverman

The latest drug development news and highlights from our FDA Performance Tracker.

More from Archive

More from Pink Sheet